Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models

Experimental Eye Research

Volumn 91, Issue 1, 2010, Pages 85-91

  Kida, Tetsuo ^a   Fujii, Atsuko ^a   Sakai, Osamu ^a   Iemura, Masahito ^a   Atsumi, Ikuyo ^a   Wada, Tomoyuki ^a   Sakaki, Hideyuki ^a  

^a SENJU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Allergic conjunctivitis; Bepotastine besilate; Eosinophil; Guinea pig; Histamine H1 receptor antagonist; Mast cell; Platelet activating factor; TAU 284

Indexed keywords

BETOTASTINE; HISTAMINE; KETOTIFEN; KETOTIFEN FUMARATE; LEUKOTRIENE B4; LEVOCABASTINE; OLOPATADINE; OVALBUMIN; THROMBOCYTE ACTIVATING FACTOR;

ALLERGIC CONJUNCTIVITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MEMBRANE PERMEABILITY; CHEMOTAXIS; CONTROLLED STUDY; EOSINOPHIL; EOSINOPHIL INFILTRATION; GUINEA PIG; HISTAMINE RELEASE; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE MIGRATION; MALE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

ANIMALS; CAPILLARY PERMEABILITY; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; CONJUNCTIVA; CONJUNCTIVITIS, ALLERGIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EOSINOPHILS; GUINEA PIGS; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HISTAMINE RELEASE; LEUKOTRIENE B4; MALE; MAST CELLS; OVALBUMIN; PERITONEAL CAVITY; PIPERIDINES; PLATELET ACTIVATING FACTOR; PYRIDINES; RATS; RATS, WISTAR;

EID: 77953363761     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2010.04.006     Document Type: Article

References (30)

1. Abelson M.B., Chapin M.J. Current and future topical treatments for ocular allergy. Compr. Ophthalmol. Update 2000, 1:303-317.
2. Abelson M.B., Smith L., Chapin M. Ocular allergic disease: mechanisms, disease sub-types, treatment. Ocul. Surf. 2003, 1:127-149.
3. Abelson M.B., Torkildsen G.L., Williams J.I., Gow J.A., Gomes P.J., McNamara T.R., Bepotastine Besilate Ophthalmic Solutions Clinical Study Group Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin. Ther. 2009, 31:1908-1921.
4. 4 action in mice. Eur. J. Pharmacol. 2006, 54:59-64.
5. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J. Allergy Clin. Immunol. 2000, 106:1019-1032.
6. Bielory L., Lien K.W., Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005, 65:215-228.
7. Bonini S., Magrini L., Rotiroti G., Lambiase A., Tomassini M., Rumi C., Bonini S. The eosinophil and the eye. Allergy 1997, 52:44-47.
8. Calder V.L., Lackie P.M. Basic science and pathophysiology of ocular allergy. Curr. Allergy Asthma Rep. 2004, 4:326-331.
9. Groneberg D.A., Bielory L., Fischer A., Bonini S., Wahn U. Animal models of allergic and inflammatory conjunctivitis. Allergy 2003, 58:1101-1113.
10. Honda H., Murata K., Hamazaki A., Sakamoto O., Ueno H., Fujiwara H. Inhibitory effect of betotastine on anaphylactic and histamine-induced reactions in guinea pigs. Jpn. Pharmacol. Ther. 1997, 25:879-888.
11. Kaminuma O., Ogawa K., Kikkawa H., Kikuchi M., Naito K., Ikezawa K. A novel anti-allergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells. Biol. Pharm. Bull. 1998, 21:411-413.
12. Katayama S., Shionoya H., Ohtake S. A new method for extraction of extravasated dye in the skin and the influence of fasting stress on passive cutaneous anaphylaxis in guinea pigs and rats. Microbiol. Immunol. 1978, 22:89-101.
13. Kato M., Nishida A., Aga Y., Kita J., Kudo Y., Narita H., Endo T. Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate. Arzneimittelforschung 1997, 47(II):1116-1124.
14. 4 by n-3 polyunsaturated fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 1998, 58:243-248.
15. Kobayashi M., Kabashima K., Nakamura M., Tokura Y. Downmodulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and CD54 expression in human keratinocytes. Skin Pharmacol. Physiol. 2009, 22:45-48.
16. Lee J.S., Lee J.E., Kim N., Oum B.S. Comparison of the conjunctival toxicity of topical ocular antiallergic agents. J. Ocul. Pharmacol. Ther. 2008, 24:557-562.
17. Leonardi A., Domonicis C.D., Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr. Opin. Allergy Clin. Immunol. 2007, 7:429-435.
18. Mota I., Perini A. A heat labile mercaptoethanol susceptible homocytotropic antibody in the guinea pig. Life Sci. 1970, 9:923-930.
19. Murata T., Matsumoto Y., Suzuki T., Naito K., Takata I., Tsuzurahara K. Effect of betotastine besilate (TAU-284), a novel anti-allergic agent, on experimental allergic rhinitis. Jpn. J. Allergol. 1997, 46:576-584.
20. Narita H., Kikuchi M., Asahi T., Inamatsu M., Odawara A., Kinoshita K., Shimazaki T., Hoshiyama M., Magaribuchi T., Yamamura M., Yato N., Yoneda H. General pharmacology of betotastine besilate (TAU-284). Jpn. Pharmacol. Ther. 1997, 25:907-924.
21. 4 on eosinophil infiltration in response to C5a in guinea-pig skin. Br. J. Pharmacol. 1994, 113:117-120.
22. Sakai A., Kikuchi M., Yato N., Kikkawa S., Saito N., Narita H. Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice. Arzneimittelforschung 1997, 47(II):954-958.
23. Sakamoto O., Okanari E., Ueno H. Effect of betotastine on experimental asthma induced in guinea pigs. Jpn. Pharmacol. Ther. 1997, 25:889-894.
24. Schoch C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J. Ocul. Pharmacol. Ther. 2003, 19:75-81.
25. Schoch C. Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat. Ocul. Immunol. Inflamm. 2005, 13:39-44.
26. Shirley E. A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. Biometrics 1977, 33:386-389.
27. Tanizaki H., Kambe N., Nakamura Y., Tanaka A., Matsuda H., Miyachi Y. Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice. Int. Arch. Allergy Immunol. 2008, 145:277-282.
28. Ueno M., Inagaki N., Nagai H., Koda A. Antiallergic action of betotastine besilate (TAU-284) in animal models: a comparison with ketotifen. Pharmacology 1998, 57:206-214.
29. Yanni J.M., Stephens D.J., Miller S.T., Weimer L.K., Graff G., Parnell D., Lang L.S., Spellman J.M., Brady M.T., Gamache D.A. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J. Ocul. Pharmacol. Ther. 1996, 12:389-400.
30. Yato N., Murata T., Saito N., Sakai A., Kikuchi M., Tsuzurahara K., Narita H. Anti-allergic activity of betotastine besilate (TAU-284), a new anti-allergic drug. Folia Pharmacol. Jpn. 1997, 110:19-29.